8 results
10-K
2023 FY
TSBX
Turnstone Biologics Corp
21 Mar 24
Annual report
8:51pm
of the tumor, tumor escape and treatment-resistant tumor growth.
TILs: TIL therapies are a type of ACT whereby lymphocytes including T cells are extracted
424B4
TSBX
Turnstone Biologics Corp
21 Jul 23
Prospectus supplement with pricing info
7:14pm
not be expressed uniformly across the tumor cells, and this heterogeneity can lead to ineffective targeting of the tumor, tumor escape and treatment-resistant
S-1/A
TSBX
Turnstone Biologics Corp
23 Jun 23
IPO registration (amended)
9:49pm
targeting of the tumor, tumor escape and treatment-resistant tumor growth.
TILs: TIL therapies are a type of ACT whereby lymphocytes including T
S-1
TSBX
Turnstone Biologics Corp
12 Jun 23
IPO registration
4:28pm
targeting of the tumor, tumor escape and treatment-resistant tumor growth.
TILs: TIL therapies are a type of ACT whereby lymphocytes including T cells
S-1
EX-10.9
7lk942zm70zk18oq
12 Jun 23
IPO registration
4:28pm
DRS
EX-10.9
6n48fpljv8er
15 May 23
Draft registration statement
12:00am
DRS
ycicesk 81fkuph6txs6
15 May 23
Draft registration statement
12:00am
- Prev
- 1
- Next